Your session is about to expire
← Back to Search
DCV for Breast Cancer
Study Summary
This trial tests a new cancer treatment, DCV, on breast cancer patients with brain involvement, to find the safest dose.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2013 Phase 2 trial • 11 Patients • NCT00323115Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Dendritic Cell (DC) Vaccine dose escalation
Frequently Asked Questions
What is the current cohort size of this clinical investigation?
"Affirmative. Clinicaltrials.gov provides information that this medical trial, first posted on March 28th 2023, is actively seeking participants from one location and requires 18 patients in total."
Are there any vacancies left for participants in this trial?
"Affirmative. Clinicaltrials.gov records the commencement of this trial on March 28th, 2023 and its most recent update was performed two days later. The study is endeavoring to enroll 18 individuals from one specific medical centre."
Has the FDA granted authorization for a stepped-up dosage of Dendritic Cell Vaccine?
"The risk of Dendritic Cell (DC) Vaccine dose escalation is estimated to be a 1 on our team's scale, as this is an early phase trial that has provided limited evidence regarding efficacy and safety."
Share this study with friends
Copy Link
Messenger